Eloxx Pharmaceuticals, Inc. (ELOX): Total Liabilities
$17.18M
As of 2025-12-31
-18.5%
3-year compound annual growth
+1.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.18M | -37.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $27.31M | +12.3% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $24.31M | -23.5% | 2026-03-17, Balance as of period end |
| 2022-12-31 | $31.78M | +39.7% | 2023-03-31, Balance as of period end |
| 2021-12-31 | $22.75M | +40.1% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $16.25M | -28.5% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $22.73M | +191.2% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $7.81M | n/a | 2020-03-06, Balance as of period end |
| No annual figure between 2017-06-30 and 2018-12-31. | |||
| 2017-06-30 | $4.97M | +6.6% | 2017-10-13, Balance as of period end |
| 2016-06-30 | $4.67M | -36.3% | 2017-10-13, Balance as of period end |
| 2015-06-30 | $7.32M | +25.3% | 2016-10-13, Balance as of period end |
| 2014-06-30 | $5.84M | +76.5% | 2015-10-09, Balance as of period end |
| 2013-06-30 | $3.31M | -5.4% | 2014-09-29, Balance as of period end |
| 2012-06-30 | $3.50M | -14.2% | 2013-09-11, Balance as of period end |
| 2011-06-30 | $4.08M | n/a | 2012-10-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $17.18M | -37.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare ELOX, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗